Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The proposed study is for a 6 week open-label clinical trial in which Seroquel XR is added to a selective serotonin reuptake inhibitor (SSRI) medication for the treatment of depressive and/or anxiety symptoms. Each subject will self-report changes in symptoms, functional impairment, etc. on a twice daily basis using a handheld computer (HHC) that transmits real-time symptoms reports to a central database. Each subject will be assessed in-person on a weekly or biweekly basis during the course of the study.
Condition or disease
Depressive Disorder, Major
Drug: Quetiapine (Seroquel) XR
This study is a 6-week open-label clinical trial in which Seroquel XR is added to an antidepressant medication for the treatment of MDD with or without comorbid generalized anxiety disorder. Patients who are currently experiencing a depressive episode that has not responded to an adequate trial of an antidepressant will be eligible to participate. During the course of augmentation treatment with Seroquel XR, each subject will regularly enter information on symptom severity and functional impairment into their handheld computer, and this information will be wirelessly transmitted to a central database.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of major depressive disorder, currently depressed with or without a comorbid generalized anxiety disorder as determined by DSM-IV diagnostic criteria (confirmed using the MINI)
17-item Hamilton Depression Rating Scale (HAM-D) score of ≥ 18
Treatment with any of the following antidepressant medications for the past 4 weeks at a minimum therapeutic dose
Diagnosis of a past or current bipolar disorder
Current psychotic symptoms
Substance-induced mood disorder
Substance or alcohol dependence
Prominent current suicidal ideation as defined by a HAM-D item 3 (suicide item) score of ≥ 3
Current treatment with more than one antidepressant medication
Current treatment with an tricyclic (TCA) antidepressant or monoamine oxidase inhibitor (MAOI)